These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 10588979)
1. Moisture transport into chlorofluorocarbon-free metered dose inhalers. Williams G J Allergy Clin Immunol; 1999 Dec; 104(6):S227-9. PubMed ID: 10588979 [TBL] [Abstract][Full Text] [Related]
2. Compatibility evaluation of metered-dose inhaler valve elastomers with tetrafluoroethane (P134a), a non-CFC propellant. Tiwari D; Goldman D; Dixit S; Malick WA; Madan PL Drug Dev Ind Pharm; 1998 Apr; 24(4):345-52. PubMed ID: 9876594 [TBL] [Abstract][Full Text] [Related]
3. The chlorofluorocarbon to hydrofluoroalkane transition: the effect on pressurized metered dose inhaler suspension stability. Brindley A J Allergy Clin Immunol; 1999 Dec; 104(6):S221-6. PubMed ID: 10588978 [TBL] [Abstract][Full Text] [Related]
4. Hydrofluoroalkane mandate in effect January 1, 2009: Switch from chlorofluorocarbon- to hydrofluoroalkane-propelled inhalers requires active transition. Peters S Clin Cornerstone; 2009; 9(3):50-3. PubMed ID: 19781516 [TBL] [Abstract][Full Text] [Related]
5. The challenge of reformulation. Smith IJ J Aerosol Med; 1995; 8 Suppl 1():S19-27. PubMed ID: 10150491 [TBL] [Abstract][Full Text] [Related]
7. Transition to CFC-free metered dose inhalers--into the new millennium. McDonald KJ; Martin GP Int J Pharm; 2000 May; 201(1):89-107. PubMed ID: 10867268 [TBL] [Abstract][Full Text] [Related]
8. Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug delivery system. Ross DL; Gabrio BJ J Aerosol Med; 1999; 12(3):151-60. PubMed ID: 10623331 [TBL] [Abstract][Full Text] [Related]
9. The role of international environmental agreements in metered-dose inhaler technology changes. Forte R; Dibble C J Allergy Clin Immunol; 1999 Dec; 104(6):S217-20. PubMed ID: 10588977 [TBL] [Abstract][Full Text] [Related]
10. Moisture uptake and its influence on pressurized metered-dose inhalers. Williams RO; Hu C Pharm Dev Technol; 2000; 5(2):153-62. PubMed ID: 10810745 [TBL] [Abstract][Full Text] [Related]
11. Issues surrounding MDI formulation development with non-CFC propellants. Kontny MJ; Destefano G; Jager PD; McNamara DP; Turi JS; Van Campen L J Aerosol Med; 1991; 4(3):181-7. PubMed ID: 10147677 [TBL] [Abstract][Full Text] [Related]
12. Protein conformational stability in the hydrofluoroalkane propellants tetrafluoroethane and heptafluoropropane analysed by Fourier transform Raman spectroscopy. Quinn EA; Forbes RT; Williams AC; Oliver MJ; McKenzie L; Purewal TS Int J Pharm; 1999 Sep; 186(1):31-41. PubMed ID: 10469921 [TBL] [Abstract][Full Text] [Related]
13. Influence of propellant composition on drug delivery from a pressurized metered-dose inhaler. Williams RO; Repka M; Liu J Drug Dev Ind Pharm; 1998 Aug; 24(8):763-70. PubMed ID: 9876524 [TBL] [Abstract][Full Text] [Related]
14. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Gabrio BJ; Stein SW; Velasquez DJ Int J Pharm; 1999 Sep; 186(1):3-12. PubMed ID: 10469919 [TBL] [Abstract][Full Text] [Related]
15. The change to non-CFC metered dose inhalers. Rubinfeld A Aust Fam Physician; 1997 Dec; 26(12):1412-4. PubMed ID: 9470296 [TBL] [Abstract][Full Text] [Related]
16. Switching to CFC-free beclometasone for asthma. Drug Ther Bull; 2008 Jun; 46(6):46-8. PubMed ID: 18525059 [TBL] [Abstract][Full Text] [Related]